Anti-Müllerian Hormone (AMH)

← Back to Lab Reference Library

Category: Hormone Health  |  Also known as: AMH, Müllerian Inhibiting Substance, MIS  |  Sample: Serum (any cycle day; fasting not required)

1. What This Test Measures

Anti-Müllerian hormone (AMH) is a glycoprotein belonging to the transforming growth factor beta (TGF-beta) superfamily. In women of reproductive age, AMH is produced by the granulosa cells of small antral and pre-antral ovarian follicles. Each of these follicles represents a maturing egg that has been recruited from the primordial follicle pool. The number of small antral follicles producing AMH at any given time is directly proportional to the total number of primordial follicles remaining in the ovaries, making serum AMH the most reliable single blood marker of ovarian reserve.

Unlike FSH and estradiol, which fluctuate significantly across the menstrual cycle and must be measured on cycle day 2 to 3 for accurate interpretation, AMH remains relatively stable throughout the cycle. This cycle-independence is one of its primary clinical advantages: AMH can be drawn at any time, in any cycle, without scheduling constraints. AMH is also not significantly affected by hormonal contraceptives (though some studies suggest a modest suppression with combined oral contraceptives), making it a more accessible screening test than FSH in women on birth control.

Women are born with a fixed number of primordial follicles (approximately 1 to 2 million at birth, declining to approximately 300,000 to 500,000 at puberty). This pool cannot be replenished. Each menstrual cycle recruits a cohort of follicles, one of which is selected for ovulation while the remainder undergo atresia (programmed cell death). AMH declines progressively as the primordial pool is depleted, becoming undetectable approximately 5 years before menopause. The rate of decline varies significantly between individuals, which is why two women of the same age can have very different AMH levels and very different remaining reproductive windows.

2. Why This Test Matters

• Ovarian reserve assessment: AMH is the best single predictor of how many eggs remain. This information is critical for fertility planning, IVF counseling, and reproductive timeline decisions
• IVF response prediction: AMH is the strongest predictor of ovarian response to gonadotropin stimulation. Low AMH predicts fewer eggs retrieved per IVF cycle. High AMH predicts robust response with increased risk of ovarian hyperstimulation syndrome (OHSS). IVF protocol selection (dosing, drug choice) is guided by AMH
• PCOS diagnosis: elevated AMH (above 4.0 to 5.0 ng/mL) reflects the excessive number of small antral follicles characteristic of polycystic ovary syndrome. AMH is increasingly used as a PCOS diagnostic criterion, particularly when ultrasound antral follicle count is not available
• Premature ovarian insufficiency (POI): AMH below 0.5 ng/mL in a woman under 40 raises concern for POI (premature menopause), which requires further evaluation with FSH, estradiol, and potentially genetic testing
• Fertility preservation counseling: AMH helps women decide whether and when to pursue egg freezing by providing an objective measure of their remaining reproductive window
• Menopausal transition prediction: AMH decline accelerates in the years preceding menopause. Very low AMH (below 0.2 ng/mL) suggests menopause is likely within 4 to 5 years
• Gonadotoxic therapy planning: AMH measured before chemotherapy or ovarian surgery establishes the baseline for assessing post-treatment ovarian damage

3. Standard Lab Reference Range

AMH Level	General Classification	Clinical Context
Above 4.0 ng/mL	High	Possible PCOS; robust reserve in young women without PCOS features
1.5 to 4.0 ng/mL	Normal	Adequate ovarian reserve for age in most reproductive-age women
1.0 to 1.5 ng/mL	Low normal	Declining reserve; age-dependent interpretation essential
0.5 to 1.0 ng/mL	Low	Diminished ovarian reserve; fertility intervention may be time-sensitive
Below 0.5 ng/mL	Very low	Severely diminished reserve; approaching menopause or POI in young women

4. Optimal Functional Medicine Range

Age	Expected AMH (ng/mL)	Functional Interpretation
25 to 30	2.5 to 6.0	Peak reserve; values below 2.0 warrant early fertility counseling
30 to 35	1.5 to 4.0	Adequate; values below 1.5 suggest accelerated decline
35 to 38	1.0 to 3.0	Active decline expected; values below 1.0 are time-sensitive for fertility
38 to 42	0.5 to 2.0	Significant decline; values below 0.5 indicate very limited window
Above 42	Below 1.0	Perimenopause likely; undetectable AMH expected within 3 to 5 years

5. AMH in the Complete Reproductive Panel

AMH is one component of a comprehensive reproductive and hormonal assessment:

Marker	What It Adds	When to Draw
AMH (this page)	Ovarian reserve (egg quantity)	Any cycle day
FSH	Pituitary drive; rising FSH reflects declining ovarian feedback	Cycle day 2 to 3
Estradiol	Early follicular estrogen; needed to interpret FSH accurately	Cycle day 2 to 3
LH	Ovulation trigger; LH:FSH ratio elevated in PCOS	Cycle day 2 to 3
Progesterone	Confirms ovulation; mid-luteal (cycle day 21) measurement	Cycle day 21
DHEA-S	Adrenal androgen contribution; supplemented in diminished reserve	Any day

6. Symptoms Associated With Abnormal AMH

7. What Causes Abnormal AMH Levels

• Natural age-related decline: the most common cause of low AMH. The primordial follicle pool is fixed at birth and depletes irreversibly with age. The rate of decline varies between individuals due to genetics, environmental exposures, and lifestyle factors
• Premature ovarian insufficiency (POI): AMH below 0.5 ng/mL in women under 40 suggests premature depletion of the follicle pool. Causes include autoimmune ovarian damage, genetic factors (FMR1 premutations, Turner syndrome mosaicism), and idiopathic POI
• Ovarian surgery: removal of ovarian tissue (cystectomy, oophorectomy) directly reduces the follicle pool and AMH. Even conservative surgery for endometriomas can significantly reduce AMH in the operated ovary
• Chemotherapy and radiation: gonadotoxic treatments damage primordial follicles and can produce permanent AMH reduction or undetectable AMH
• Smoking: cigarette smoking accelerates follicular atresia and produces lower AMH compared to non-smokers of the same age. Smoking advances menopause by approximately 1 to 4 years
• PCOS (elevated AMH): the excessive antral follicle count in PCOS produces elevated AMH, often above 4.0 to 5.0 ng/mL. This reflects follicular excess and anovulation, not superior fertility
• Insulin resistance: hyperinsulinemia drives ovarian androgen production and contributes to the anovulatory pattern of PCOS, which is associated with elevated AMH
• Vitamin D deficiency: emerging evidence suggests that vitamin D receptors in granulosa cells may influence AMH production, with some studies showing modest AMH improvements after vitamin D repletion

8. How to Support Ovarian Health and Egg Quality

9. Related Lab Tests

10. When Testing Is Recommended

• Any woman over 30 who wants to understand her reproductive timeline and remaining fertile window
• Women considering fertility preservation (egg or embryo freezing): AMH guides the decision and predicts the number of eggs likely to be retrieved
• Infertility evaluation: AMH is part of the standard initial workup for any couple having difficulty conceiving
• Suspected PCOS: AMH above 4.0 to 5.0 ng/mL supports the diagnosis alongside clinical features and other lab findings
• Before IVF: AMH determines the stimulation protocol, expected response, and OHSS risk
• Family history of early menopause or premature ovarian insufficiency
• Before gonadotoxic therapy (chemotherapy, pelvic radiation): baseline AMH establishes the pre-treatment ovarian reserve
• Evaluate alongside FSH, estradiol, LH, and antral follicle count (ultrasound) for the most complete ovarian reserve assessment

11. Clinical Perspective

12. Frequently Asked Questions